Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Investigation of the role of tyrosine kinase receptor EPHA3 in colorectal cancer

  • Andretta, Elena
  • Cartón-Garcia, Fernando|||0000-0002-1858-6551
  • Martínez-Barriocanal, Águeda|||0000-0002-8809-160X
  • de Marcondes, Priscila Guimarães|||0000-0001-7271-2881
  • Jimenez-Flores, Lizbeth M.
  • Macaya, Irati|||0000-0001-5698-6452
  • Bazzocco, Sarah
  • Bilic Zimmermann, Josipa|||0000-0001-9642-6265
  • Rodrigues, Paulo|||0000-0002-5380-2715
  • Nieto Raya, Rocio|||0000-0001-8567-2268
  • Landolfi, Stefania|||0000-0002-1059-635X
  • Ramón y Cajal, Santiago|||0000-0002-3867-1390
  • Schwartz, Simon|||0000-0001-8297-7971
  • Brown, Arthur
  • Dopeso, Higinio|||0000-0003-0060-1861
  • Arango, Diego|||0000-0003-2953-3284
EPH signaling deregulation has been shown to be important for colorectal carcinogenesis and genome-wide sequencing efforts have identified EPHA3 as one of the most frequently mutated genes in these tumors. However, the role of EPHA3 in colorectal cancer has not been thoroughly investigated. We show here that ectopic expression of wild type EPHA3 in colon cancer cells did not affect their growth, motility/invasion or metastatic potential in vivo. Moreover, overexpression of mutant EPHA3 or deletion of the endogenous mutant EPHA3 in colon cancer cells did not affect their growth or motility. EPHA3 inactivation in mice did not initiate the tumorigenic process in their intestine, and had no effects on tumor size/multiplicity after tumor initiation either genetically or pharmacologically. In addition, immunohistochemical analysis of EPHA3 tumor levels did not reveal associations with survival or clinicopathological features of colorectal cancer patients. In conclusion, we show that EPHA3 does not play a major role in colorectal tumorigenesis. These results significantly contribute to our understanding of the role of EPH signaling during colorectal carcinogenesis, and highlighting the need for detailed functional studies to confirm the relevance of putative cancer driver genes identified in sequencing efforts of the cancer genome.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Myo5b knockout mice as a model of microvillus inclusion disease

  • Cartón-Garcia, Fernando|||0000-0002-1858-6551
  • Overeem, Arend W.
  • Nieto Raya, Rocio|||0000-0001-8567-2268
  • Bazzocco, Sarah
  • Dopeso, Higinio|||0000-0003-0060-1861
  • Macaya, Irati|||0000-0001-5698-6452
  • Bilic Zimmermann, Josipa|||0000-0001-9642-6265
  • Landolfi, Stefania|||0000-0002-1059-635X
  • Hernandez-Losa, Javier|||0000-0003-1526-3201
  • Schwartz, Simon|||0000-0001-8297-7971
  • Ramón y Cajal, Santiago|||0000-0002-3867-1390
  • van Ijzendoorn, Sven C. D.
  • Arango, Diego|||0000-0003-2953-3284
Inherited MYO5B mutations have recently been associated with microvillus inclusion disease (MVID), an autosomal recessive syndrome characterized by intractable, life-threatening, watery diarrhea appearing shortly after birth. Characterization of the molecular mechanisms underlying this disease and development of novel therapeutic approaches is hampered by the lack of animal models. In this study we describe the phenotype of a novel mouse model with targeted inactivation of Myo5b. Myo5b knockout mice show perinatal mortality, diarrhea and the characteristic mislocalization of apical and basolateral plasma membrane markers in enterocytes. Moreover, in transmission electron preparations, we observed microvillus atrophy and the presence of microvillus inclusion bodies. Importantly, Myo5b knockout embryos at day 20 of gestation already display all these structural defects, indicating that they are tissue autonomous rather than secondary to environmental cues, such as the long-term absence of nutrients in the intestine. Myo5b knockout mice closely resemble the phenotype of MVID patients and constitute a useful model to further investigate the underlying molecular mechanism of this disease and to preclinically assess the efficacy of novel therapeutic approaches.